e-learning
resources
London 2016
Tuesday, 06.09.2016
Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
LATE-BREAKING ABSTRACT: Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?
Remco S. Djamin (Breda, Netherlands), Remco S. Djamin, Sevim Uzun, Anton A.M. Ermens, Rene Kerstens, Henk C. Hoogsteden, Joachim G.J.V. Aerts, Menno M. van der Eerden
Source:
International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases
Session:
Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases
Session type:
Thematic Poster
Number:
3713
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Remco S. Djamin (Breda, Netherlands), Remco S. Djamin, Sevim Uzun, Anton A.M. Ermens, Rene Kerstens, Henk C. Hoogsteden, Joachim G.J.V. Aerts, Menno M. van der Eerden. LATE-BREAKING ABSTRACT: Which predictors in COPD patients with the frequent exacerbator phenotype predict the treatment response to maintenance therapy with azithromycin?. Eur Respir J 2016; 48: Suppl. 60, 3713
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Risk factors of adverse outcome after acute hospitalization in Idiopathic Pulmonary Fibrosis (IPF)
Related content which might interest you:
LATE-BREAKING ABSTRACT: Predictive factors of frequent exacerbations in mild grade COPD patients
Source: International Congress 2016 – Managing multimorbidity and lifestyle change in primary care
Year: 2016
LATE-BREAKING ABSTRACT: Exacerbation phenotype directed corticosteroid therapy of COPD: Value of blood eosinophilia (primary results)
Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice
Year: 2015
LATE-BREAKING ABSTRACT: Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels
Source: International Congress 2015 – Emerging strategies for airway disease treatments
Year: 2015
Treatment failure of hospitalized patients with COPD exacerbation using systemic corticosteroids plus antibiotics: Role of early inflammatory predictors
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study
Source: International Congress 2016 – Novel strategies on COPD and asthma management
Year: 2016
Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability
Source: International Congress 2014 – Markers
Year: 2014
LATE-BREAKING ABSTRACT: An algorithm for the identification of clinical COPD phenotypes in daily practice
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016
COPD on anti-GERD therapy remains at higher risk for severe exacerbation
Source: International Congress 2014 – COPD exacerbations
Year: 2014
LATE-BREAKING ABSTRACT: beta-blockers are associated with a reduction in COPD exacerbations in COPDGene
Source: International Congress 2014 – COPD exacerbations
Year: 2014
LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014
LATE-BREAKING ABSTRACT: Validation of the DECAF score to predict hospital mortality in exacerbations of COPD
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
LATE-BREAKING ABSTRACT: Single inhaler triple therapy (ICS/LAMA/LABA) in patients with advanced COPD: Results of the FULFIL trial
Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities
Year: 2016
LATE-BREAKING ABSTRACT: Stratification of patients with COPD by frequence of exacerbations is an essential step for what to treat in COPD. - A survey in a real life COPD population
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
Do inhaled corticosteroids reduce the frequent exacerbator phenotype in COPD - A little help by a multicenter survey
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
LATE-BREAKING ABSTRACT: Can patients with COPD assimilate disease specific information at a time of being acutely unwell due to an exacerbation of their disease?
Source: International Congress 2016 – Best abstracts on innovative outcomes and novel interventions in respiratory physiotherapy
Year: 2016
LATE-BREAKING ABSTRACT: Effects of a fixed dose once-daily triple drug combination in smokers and non-smokers with COPD
Source: International Congress 2016 – Features and impact of comorbidities in COPD
Year: 2016
CRP as predictor as predictor for late treatment failure in hospitalised patients with AECOPD
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
The role of IFN-γ in severe COPD patients with anamnestic viral-induced exacerbations before and after roflumilast treatment
Source: International Congress 2016 – Translational studies in lung disease
Year: 2016
LATE-BREAKING ABSTRACT: Evaluating blood eosinophils and exacerbation history to predict ICS response in COPD
Source: International Congress 2016 – Late-breaking topics in airways disease
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept